kynurenine has been researched along with Bipolar Disorder in 49 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The balance between neurotoxic and neuroprotective effects of kynurenine pathway (KP) components has been recently proposed as a key element in the pathophysiology of bipolar disorder (BD) and related mood episodes." | 9.22 | The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2022) |
| "Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD)." | 9.12 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2021) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 9.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "There has been growing scientific evidence in recent years that bipolar disorder (BD) is associated with alterations in the kynurenine (KYN) pathway." | 8.02 | Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study. ( Benevenuto, D; Fries, GR; Kahlon, R; Kazimi, IF; Kurian, S; Quevedo, J; Saxena, J; Saxena, K; Scaini, G; Soares, JC; Valvassori, SS; Zeni, CP, 2021) |
| "Mania and chronic depressive symptoms in BD are accompanied by a strong interaction between inflammation and a potentially neurotoxic kynurenine metabolism." | 7.96 | A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder. ( Coppens, V; de Boer, P; Fransen, E; Lai, FY; Morrens, M; Sabbe, B; Schuermans, J; Timmers, M; van den Ameele, S; van Diermen, L; van Nuijs, AL; Verkerk, R, 2020) |
| "Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders." | 7.96 | Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. ( Agartz, I; Andreassen, OA; Bogdanov, M; Dieset, I; Djurovic, S; Hope, S; Jönsson, EG; Kaddurah-Daouk, R; Matson, W; Melle, I; Smeland, OB; Steen, NE; Vedal, TSJ, 2020) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| " Activation of indoleamine 2-3 dioxygenase following a pro-inflammatory state could reduce the amount of tryptophan converted to serotonin and increase the production of tryptophan catabolites such as kynurenic acid, an antagonist of ionotropic excitatory aminoacid receptors, whose levels are reduced in bipolar disorder." | 7.88 | Kynurenine pathway and white matter microstructure in bipolar disorder. ( Benedetti, F; Bollettini, I; Colombo, C; Grillitsch, D; Locatelli, C; Mazza, E; Myint, AM; Poletti, S; Schüetze, G; Schwarz, M, 2018) |
| "Inflammation-related changes in the concentrations of kynurenine-pathway metabolites occur in depression secondary to medical conditions but have not been well characterized in primary bipolar disorder (BD), with contradictory results potentially attributable to the presence or absence of psychosis and/or medication effects." | 7.81 | Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. ( Bellgowan, PS; Bodurka, J; Dantzer, R; Drevets, WC; Ford, BN; Savitz, J; Teague, TK; Victor, TA; Wurfel, BE, 2015) |
| "We investigated the tryptophan-kynurenine metabolism pathway as a proxy of dysregulated inflammatory homeostasis in euthymic, overweight individuals with BD (n = 78) compared to healthy controls (n = 156)." | 7.80 | Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. ( Bengesser, SA; Birner, A; Fuchs, D; Geisler, S; Hecht, K; Kapfhammer, HP; Kattnig, F; Lackner, N; Mangge, H; McIntyre, RS; Reininghaus, B; Reininghaus, EZ; Unterweger, R; Zelzer, S, 2014) |
| "Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder." | 7.75 | Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. ( Leonard, S; Miller, CL; Murakami, P; Ross, RG; Ruczinski, I; Sinkus, M; Sullivan, B, 2009) |
| "Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder." | 7.74 | Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. ( Cwik, M; Llenos, IC; Miller, CL; Walkup, J; Weis, S, 2008) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 6.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 5.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Chronic, low-level inflammation is associated with symptomatic bipolar disorder (BD) and with chronic insomnia." | 5.48 | Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. ( Can, A; Fuchs, D; Groer, M; Krishnamurthy, VB; Millett, CE; Mukherjee, D; Postolache, TT; Reider, A; Saunders, EFH, 2018) |
| "Kynurenine is an intermediate in the inflammatory cascade and can be peripherally measured to proxy inflammatory activity." | 5.46 | Tryptophan breakdown and cognition in bipolar disorder. ( Bengesser, SA; Birner, A; Dalkner, N; Fellendorf, FT; Fuchs, D; Hamm, C; Herzog-Eberhard, S; Hörmanseder, C; Kainzbauer, N; Maget, A; Mangge, H; Mansur, RB; McIntyre, RS; Moll, N; Pilz, R; Platzer, M; Queissner, R; Rauch, P; Reininghaus, EZ; Schütze, G; Schwarz, MJ; Zelzer, S, 2017) |
| "The balance between neurotoxic and neuroprotective effects of kynurenine pathway (KP) components has been recently proposed as a key element in the pathophysiology of bipolar disorder (BD) and related mood episodes." | 5.22 | The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2022) |
| "Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD)." | 5.12 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2021) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 5.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "There has been growing scientific evidence in recent years that bipolar disorder (BD) is associated with alterations in the kynurenine (KYN) pathway." | 4.02 | Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study. ( Benevenuto, D; Fries, GR; Kahlon, R; Kazimi, IF; Kurian, S; Quevedo, J; Saxena, J; Saxena, K; Scaini, G; Soares, JC; Valvassori, SS; Zeni, CP, 2021) |
| "Mania and chronic depressive symptoms in BD are accompanied by a strong interaction between inflammation and a potentially neurotoxic kynurenine metabolism." | 3.96 | A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder. ( Coppens, V; de Boer, P; Fransen, E; Lai, FY; Morrens, M; Sabbe, B; Schuermans, J; Timmers, M; van den Ameele, S; van Diermen, L; van Nuijs, AL; Verkerk, R, 2020) |
| "Although prone to residual confounding, the present results suggest the kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system dysfunction as trait factors in schizophrenia spectrum and bipolar disorders." | 3.96 | Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. ( Agartz, I; Andreassen, OA; Bogdanov, M; Dieset, I; Djurovic, S; Hope, S; Jönsson, EG; Kaddurah-Daouk, R; Matson, W; Melle, I; Smeland, OB; Steen, NE; Vedal, TSJ, 2020) |
| " The aim of the present study was to analyze gut microbiota composition in bipolar disorder (BD) and its relation to inflammation, serum lipids, oxidative stress, tryptophan (TRP)/kynurenine (KYN) levels, anthropometric measurements and parameters of metabolic syndrome." | 3.91 | A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. ( Bengesser, S; Birner, A; Dalkner, N; Fellendorf, F; Gorkiewicz, G; Halwachs, B; Holl, AK; Holzer, P; Kapfhammer, HP; Kashofer, K; Moll, N; Mörkl, S; Painold, A; Platzer, M; Queissner, R; Reininghaus, EZ; Schütze, G; Schwarz, MJ, 2019) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| " Activation of indoleamine 2-3 dioxygenase following a pro-inflammatory state could reduce the amount of tryptophan converted to serotonin and increase the production of tryptophan catabolites such as kynurenic acid, an antagonist of ionotropic excitatory aminoacid receptors, whose levels are reduced in bipolar disorder." | 3.88 | Kynurenine pathway and white matter microstructure in bipolar disorder. ( Benedetti, F; Bollettini, I; Colombo, C; Grillitsch, D; Locatelli, C; Mazza, E; Myint, AM; Poletti, S; Schüetze, G; Schwarz, M, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Inflammation-related changes in the concentrations of kynurenine-pathway metabolites occur in depression secondary to medical conditions but have not been well characterized in primary bipolar disorder (BD), with contradictory results potentially attributable to the presence or absence of psychosis and/or medication effects." | 3.81 | Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. ( Bellgowan, PS; Bodurka, J; Dantzer, R; Drevets, WC; Ford, BN; Savitz, J; Teague, TK; Victor, TA; Wurfel, BE, 2015) |
| "We investigated the tryptophan-kynurenine metabolism pathway as a proxy of dysregulated inflammatory homeostasis in euthymic, overweight individuals with BD (n = 78) compared to healthy controls (n = 156)." | 3.80 | Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. ( Bengesser, SA; Birner, A; Fuchs, D; Geisler, S; Hecht, K; Kapfhammer, HP; Kattnig, F; Lackner, N; Mangge, H; McIntyre, RS; Reininghaus, B; Reininghaus, EZ; Unterweger, R; Zelzer, S, 2014) |
| "Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder." | 3.75 | Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. ( Leonard, S; Miller, CL; Murakami, P; Ross, RG; Ruczinski, I; Sinkus, M; Sullivan, B, 2009) |
| "The upregulation of the initiating step of the kynurenine pathway was demonstrated in postmortem anterior cingulated cortex from individuals with schizophrenia and bipolar disorder." | 3.74 | Tryptophan breakdown pathway in bipolar mania. ( Kim, YK; Leonard, BE; Myint, AM; Park, SH; Scharpé, S; Steinbusch, HW; Verkerk, R, 2007) |
| "Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder." | 3.74 | Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. ( Cwik, M; Llenos, IC; Miller, CL; Walkup, J; Weis, S, 2008) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 2.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 1.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Chronic, low-level inflammation is associated with symptomatic bipolar disorder (BD) and with chronic insomnia." | 1.48 | Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. ( Can, A; Fuchs, D; Groer, M; Krishnamurthy, VB; Millett, CE; Mukherjee, D; Postolache, TT; Reider, A; Saunders, EFH, 2018) |
| "Kynurenine is an intermediate in the inflammatory cascade and can be peripherally measured to proxy inflammatory activity." | 1.46 | Tryptophan breakdown and cognition in bipolar disorder. ( Bengesser, SA; Birner, A; Dalkner, N; Fellendorf, FT; Fuchs, D; Hamm, C; Herzog-Eberhard, S; Hörmanseder, C; Kainzbauer, N; Maget, A; Mangge, H; Mansur, RB; McIntyre, RS; Moll, N; Pilz, R; Platzer, M; Queissner, R; Rauch, P; Reininghaus, EZ; Schütze, G; Schwarz, MJ; Zelzer, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.41) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 4 (8.16) | 29.6817 |
| 2010's | 18 (36.73) | 24.3611 |
| 2020's | 16 (32.65) | 2.80 |
| Authors | Studies |
|---|---|
| Comai, S | 2 |
| Melloni, E | 2 |
| Lorenzi, C | 1 |
| Bollettini, I | 2 |
| Vai, B | 1 |
| Zanardi, R | 1 |
| Colombo, C | 3 |
| Valtorta, F | 2 |
| Benedetti, F | 3 |
| Poletti, S | 3 |
| Hebbrecht, K | 2 |
| Morrens, M | 3 |
| Giltay, EJ | 2 |
| van Nuijs, ALN | 1 |
| Sabbe, B | 2 |
| van den Ameele, S | 2 |
| Bartoli, F | 3 |
| Cioni, RM | 3 |
| Cavaleri, D | 3 |
| Callovini, T | 3 |
| Crocamo, C | 3 |
| Misiak, B | 2 |
| Savitz, JB | 3 |
| Carrà, G | 3 |
| Sales, PMG | 3 |
| Schrage, E | 3 |
| Coico, R | 3 |
| Pato, M | 3 |
| van Nuijs, AL | 1 |
| Lai, FY | 1 |
| Schuermans, J | 1 |
| Verkerk, R | 2 |
| van Diermen, L | 1 |
| Coppens, V | 2 |
| Fransen, E | 1 |
| de Boer, P | 1 |
| Timmers, M | 1 |
| Aggio, V | 1 |
| Kadriu, B | 1 |
| Farmer, CA | 1 |
| Yuan, P | 1 |
| Park, LT | 1 |
| Deng, ZD | 1 |
| Moaddel, R | 1 |
| Henter, ID | 1 |
| Shovestul, B | 1 |
| Ballard, ED | 1 |
| Kraus, C | 1 |
| Gold, PW | 1 |
| Machado-Vieira, R | 1 |
| Zarate, CA | 1 |
| Murata, S | 1 |
| Murphy, M | 1 |
| Hoppensteadt, D | 1 |
| Fareed, J | 1 |
| Welborn, A | 1 |
| Halaris, A | 1 |
| Benevenuto, D | 1 |
| Saxena, K | 1 |
| Fries, GR | 1 |
| Valvassori, SS | 1 |
| Kahlon, R | 1 |
| Saxena, J | 1 |
| Kurian, S | 1 |
| Zeni, CP | 1 |
| Kazimi, IF | 1 |
| Scaini, G | 1 |
| Soares, JC | 2 |
| Quevedo, J | 2 |
| Marx, W | 1 |
| McGuinness, AJ | 1 |
| Rocks, T | 1 |
| Ruusunen, A | 1 |
| Cleminson, J | 1 |
| Walker, AJ | 1 |
| Gomes-da-Costa, S | 1 |
| Lane, M | 1 |
| Sanches, M | 1 |
| Diaz, AP | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Berk, M | 1 |
| Clarke, G | 1 |
| O'Neil, A | 1 |
| Jacka, F | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Fernandes, BS | 1 |
| Trepci, A | 1 |
| Sellgren, CM | 1 |
| Pålsson, E | 1 |
| Brundin, L | 1 |
| Khanlarkhani, N | 1 |
| Schwieler, L | 2 |
| Landén, M | 1 |
| Erhardt, S | 2 |
| Skorobogatov, K | 1 |
| De Picker, L | 1 |
| Kopra, E | 1 |
| Mondelli, V | 1 |
| Pariante, C | 1 |
| Nikkheslat, N | 1 |
| Wurfel, BE | 2 |
| Drevets, WC | 2 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 2 |
| Morris, HM | 1 |
| Teague, TK | 2 |
| Dantzer, R | 2 |
| Platzer, M | 5 |
| Dalkner, N | 5 |
| Fellendorf, FT | 4 |
| Birner, A | 6 |
| Bengesser, SA | 5 |
| Queissner, R | 5 |
| Kainzbauer, N | 1 |
| Pilz, R | 3 |
| Herzog-Eberhard, S | 2 |
| Hamm, C | 3 |
| Hörmanseder, C | 1 |
| Maget, A | 3 |
| Rauch, P | 2 |
| Mangge, H | 4 |
| Fuchs, D | 5 |
| Zelzer, S | 3 |
| Schütze, G | 4 |
| Moll, N | 4 |
| Schwarz, MJ | 2 |
| Mansur, RB | 1 |
| McIntyre, RS | 2 |
| Reininghaus, EZ | 6 |
| Painold, A | 2 |
| Reininghaus, B | 4 |
| Kapfhammer, HP | 5 |
| Holasek, SJ | 1 |
| Mukherjee, D | 1 |
| Krishnamurthy, VB | 1 |
| Millett, CE | 1 |
| Reider, A | 1 |
| Can, A | 1 |
| Groer, M | 1 |
| Postolache, TT | 1 |
| Saunders, EFH | 1 |
| Mörkl, S | 1 |
| Kashofer, K | 1 |
| Halwachs, B | 1 |
| Bengesser, S | 1 |
| Fellendorf, F | 1 |
| Holzer, P | 1 |
| Holl, AK | 1 |
| Gorkiewicz, G | 1 |
| Li, C | 1 |
| Wang, A | 1 |
| Wang, C | 2 |
| Ramamurthy, J | 1 |
| Zhang, E | 1 |
| Guadagno, E | 1 |
| Trakadis, Y | 1 |
| Pompili, M | 1 |
| Lionetto, L | 1 |
| Curto, M | 1 |
| Forte, A | 1 |
| Erbuto, D | 1 |
| Montebovi, F | 1 |
| Seretti, ME | 1 |
| Berardelli, I | 1 |
| Serafini, G | 1 |
| Innamorati, M | 1 |
| Amore, M | 1 |
| Baldessarini, RJ | 1 |
| Girardi, P | 1 |
| Simmaco, M | 1 |
| Takada, A | 1 |
| Shimizu, F | 1 |
| Takao, T | 1 |
| Zhou, Y | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Zhan, Y | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Li, M | 1 |
| Ning, Y | 1 |
| Steen, NE | 1 |
| Dieset, I | 1 |
| Hope, S | 1 |
| Vedal, TSJ | 1 |
| Smeland, OB | 1 |
| Matson, W | 1 |
| Kaddurah-Daouk, R | 1 |
| Agartz, I | 1 |
| Melle, I | 1 |
| Djurovic, S | 1 |
| Jönsson, EG | 1 |
| Bogdanov, M | 1 |
| Andreassen, OA | 1 |
| Hecker, A | 1 |
| Tomberger, L | 1 |
| Schwarz, M | 3 |
| Johansson, AS | 1 |
| Owe-Larsson, B | 1 |
| Asp, L | 1 |
| Kocki, T | 1 |
| Adler, M | 1 |
| Hetta, J | 1 |
| Gardner, R | 1 |
| Lundkvist, GB | 1 |
| Urbanska, EM | 1 |
| Karlsson, H | 1 |
| Geisler, S | 1 |
| Lackner, N | 1 |
| Hecht, K | 1 |
| Kattnig, F | 1 |
| Unterweger, R | 1 |
| Savitz, J | 1 |
| Victor, TA | 1 |
| Bodurka, J | 1 |
| Bellgowan, PS | 1 |
| Anderson, G | 1 |
| Jacob, A | 1 |
| Bellivier, F | 1 |
| Geoffroy, PA | 1 |
| Imbeault, S | 1 |
| Engberg, G | 1 |
| Myint, AM | 3 |
| Schüetze, G | 1 |
| Mazza, E | 1 |
| Grillitsch, D | 1 |
| Locatelli, C | 1 |
| Miller, CL | 3 |
| Murakami, P | 1 |
| Ruczinski, I | 1 |
| Ross, RG | 1 |
| Sinkus, M | 1 |
| Sullivan, B | 1 |
| Leonard, S | 1 |
| Llenos, IC | 2 |
| Dulay, JR | 1 |
| Weis, S | 2 |
| Kim, YK | 1 |
| Park, SH | 1 |
| Scharpé, S | 1 |
| Steinbusch, HW | 1 |
| Leonard, BE | 1 |
| Cwik, M | 1 |
| Walkup, J | 1 |
| Rubin, RT | 3 |
| Anokhina, IP | 1 |
| Gamaleia, NB | 1 |
| Orlikov, AB | 1 |
| Prakhye, IB | 1 |
| Ryzov, IV | 1 |
| Chouinard, G | 2 |
| Young, SN | 2 |
| Annable, L | 2 |
| Sourkes, TL | 1 |
| Møller, SE | 2 |
| Amdisen, A | 1 |
| Kirk, L | 2 |
| Moller, SE | 1 |
| Fremming, KH | 1 |
| Frazer, A | 1 |
| Pandey, GN | 1 |
| Mendels, J | 1 |
| Overall, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers[NCT01479829] | Phase 4 | 88 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.[NCT00482924] | 1,500 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia[NCT02074319] | Phase 1 | 92 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
10 reviews available for kynurenine and Bipolar Disorder
| Article | Year |
|---|---|
The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview.
Topics: Affect; Bipolar Disorder; Humans; Kynurenine; Signal Transduction; Tryptophan | 2022 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites.
Topics: Adult; Bipolar Disorder; Humans; Kynurenic Acid; Kynurenine; Observational Studies as Topic; Quinoli | 2021 |
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Schizophrenia | 2021 |
Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis.
Topics: Bipolar Disorder; Depression; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Bipolar Disorder; Cytokines; Depressive Di | 2021 |
Metabolomics in patients with psychosis: A systematic review.
Topics: 3-Hydroxybutyric Acid; Aspartic Acid; Biomarkers; Bipolar Disorder; Creatine; Female; Glutamic Acid; | 2018 |
Bipolar Disorder: The Role of the Kynurenine and Melatonergic Pathways.
Topics: Animals; Bipolar Disorder; Humans; Kynurenine; Melatonin; Signal Transduction; Tryptophan | 2016 |
The kynurenine pathway in schizophrenia and bipolar disorder.
Topics: Bipolar Disorder; Humans; Kynurenine; Metabolic Networks and Pathways; Schizophrenia | 2017 |
Kynurenines: from the perspective of major psychiatric disorders.
Topics: Animals; Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenine; Schizophrenia | 2012 |
4 trials available for kynurenine and Bipolar Disorder
| Article | Year |
|---|---|
Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression.
Topics: Bipolar Disorder; Celecoxib; Citalopram; Depressive Disorder, Treatment-Resistant; Humans; Interleuk | 2020 |
Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression.
Topics: Adrenal Cortex Hormones; Adult; Anxiety Disorders; Bipolar Disorder; Depressive Disorder; Dexamethas | 1994 |
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Evaluation; | 1979 |
A controlled clinical trial of L-tryptophan in acute mania.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Clinical Trials as Topic; Female; Humans; Kineti | 1985 |
35 other studies available for kynurenine and Bipolar Disorder
| Article | Year |
|---|---|
Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression.
Topics: Biomarkers; Bipolar Disorder; Cytokines; Depressive Disorder, Major; Humans; Kynurenine; Tryptophan; | 2022 |
The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder.
Topics: Bipolar Disorder; Cognitive Dysfunction; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptopha | 2022 |
A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder.
Topics: Adult; Affect; Biomarkers; Bipolar Disorder; C-Reactive Protein; Depression; Female; Humans; Inflamm | 2020 |
Grey and white matter structure associates with the activation of the tryptophan to kynurenine pathway in bipolar disorder.
Topics: Adult; Biomarkers; Bipolar Disorder; Brain; Female; Gray Matter; Humans; Kynurenine; Magnetic Resona | 2019 |
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Humans; Immunity; Kynurenic Acid; Kynurenine; Middle Aged | 2021 |
Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study.
Topics: Adolescent; Adult; Bipolar Disorder; Child; Humans; Kynurenic Acid; Kynurenine; Parents; Tryptophan | 2021 |
Central levels of tryptophan metabolites in subjects with bipolar disorder.
Topics: Bipolar Disorder; Chromatography, Liquid; Humans; Kynurenic Acid; Kynurenine; Tandem Mass Spectromet | 2021 |
The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites.
Topics: Bipolar Disorder; Humans; Kynurenic Acid; Kynurenine; Schizophrenia; Tryptophan | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Tryptophan breakdown and cognition in bipolar disorder.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cognition; Female; Humans; Kynurenic Acid; Kynurenine | 2017 |
The role of tryptophan metabolism and food craving in the relationship between obesity and bipolar disorder.
Topics: Adult; Bipolar Disorder; Body Mass Index; Craving; Eating; Energy Metabolism; Female; Food; Humans; | 2018 |
Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder.
Topics: Adult; Affect; Biomarkers; Bipolar Disorder; Depression; Female; Humans; Inflammation; Kynurenine; M | 2018 |
A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode.
Topics: Biomarkers; Bipolar Disorder; Case-Control Studies; Cross-Sectional Studies; Depression; Depressive | 2019 |
Tryptophan and Kynurenine Metabolites: Are They Related to Depression?
Topics: Adult; Bipolar Disorder; Case-Control Studies; Depressive Disorder, Major; Female; Humans; Hydroxyin | 2019 |
[Tryptophan Metabolites in Plasma of Patients with Depression].
Topics: Bipolar Disorder; Depressive Disorder; Humans; Kynurenine; Tryptophan | 2018 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.
Topics: Adolescent; Adult; Bipolar Disorder; Female; Humans; Kynurenine; Male; Metabolic Networks and Pathwa | 2020 |
Differences in Kynurenine Metabolism During Depressive, Manic, and Euthymic Phases of Bipolar Affective Disorder.
Topics: Adult; Bipolar Disorder; Depression; Female; Humans; Kynurenine; Male; Middle Aged; Mood Disorders | 2020 |
Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
Topics: Adult; Bipolar Disorder; Cells, Cultured; Cytokines; Female; Fibroblasts; Gene Expression Regulation | 2013 |
Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report.
Topics: Adult; Bipolar Disorder; Female; Humans; Kynurenine; Male; Middle Aged; Overweight; Tryptophan | 2014 |
Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Topics: Adult; Amygdala; Bipolar Disorder; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Male; Mi | 2015 |
Kynurenine pathway and white matter microstructure in bipolar disorder.
Topics: Adult; Bipolar Disorder; Diffusion Tensor Imaging; Female; Humans; Hydroxyindoleacetic Acid; Kynuren | 2018 |
Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Case-Control Studies; Cognition; Depression; Female; Humans; Inflamm | 2017 |
Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Black or African American; Databases, Genetic; Fem | 2009 |
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.
Topics: Adult; Analysis of Variance; Bipolar Disorder; Chromatography, High Pressure Liquid; Demography; Dep | 2006 |
Tryptophan breakdown pathway in bipolar mania.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brief Psychiatric Rating Scale; Female; Gyrus Cinguli; Human | 2007 |
Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.
Topics: 3-Hydroxyanthranilic Acid; Adult; Biomarkers; Bipolar Disorder; Brain; Chromatography, High Pressure | 2008 |
Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan.
Topics: 17-Hydroxycorticosteroids; Adrenal Glands; Bipolar Disorder; Carbon Isotopes; Female; Humans; Kynure | 1967 |
[Current biochemical conceptions of mental diseases. II. Role of changes in the biogenic amine system in the pathogenesis of affective disorders].
Topics: 3-Methoxy-4-hydroxyphenylethanol; Affective Disorders, Psychotic; Antidepressive Agents, Tricyclic; | 1980 |
Plasma neutral amino acids in mania and depression: variation during acute and prolonged treatment with L-tryptophan.
Topics: Amino Acids; Bipolar Disorder; Female; Humans; Isoleucine; Kynurenine; Leucine; Middle Aged; Tryptop | 1979 |
The effect of allopurinol on the kynurenine formation in humans following a tryptophan load.
Topics: Allopurinol; Bipolar Disorder; Humans; Kynurenine; Tryptophan | 1978 |
Plasma amino acids as an index for subgroups in manic depressive psychosis: correlation to effect of tryptophan.
Topics: Amino Acids; Bipolar Disorder; Drug Resistance; Female; Humans; Kynurenine; Male; Serotonin; Tryptop | 1976 |
Metabolism of tryptophan in depressive disease.
Topics: Adult; Bipolar Disorder; Depression; Humans; Hydroxyindoleacetic Acid; Kynurenine; Male; Metabolic C | 1973 |
Manifest psychopathology and urine biochemical measures. Multivariate analyses in manic-depressive illness.
Topics: 17-Hydroxycorticosteroids; Bipolar Disorder; Creatinine; Emotions; Factor Analysis, Statistical; Fem | 1970 |
Multiple biochemical correlates of manic-depressive illness.
Topics: 17-Hydroxycorticosteroids; Bipolar Disorder; Blood Pressure; Body Weight; Creatinine; Emotions; Huma | 1968 |